Guilford Pharmaceuticals other research news

Researchers at Johns Hopkins and the NIH announced identification of a compound that binds at a site that appears to be separate from the site where dopamine anchors to its transporter. The fact that the newly identified binding site is separate for cocaine, and does not affect dopamine's metabolism, suggests that cocaine's action can be blocked without affecting the key neurotransmitter.

While the compound is too weak to be a therapeutic candidate, it will guide the search for a treatment for cocaine addiction, the researchers said. ...